TY - JOUR
T1 - Diabetes and prostate cancer outcomes in men with nonmetastatic castrate-resistant prostate cancer
T2 - Results from the SEARCH Cohort
AU - Sergeyev, Andrei
AU - Gu, Lin
AU - De Hoedt, Amanda M.
AU - Amling, Christopher L.
AU - Aronson, William J.
AU - Cooperberg, Matthew R.
AU - Kane, Christopher J.
AU - Klaassen, Zachary
AU - Terris, Martha K.
AU - Guerrios-Rivera, Lourdes
AU - Freedland, Stephen J.
AU - Csizmadi, Ilona
N1 - Publisher Copyright:
© 2023 American Association for Cancer Research Inc.. All rights reserved.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Background: The prognosis of diabetic men with advanced prostate cancer (PC) is poorly understood and understudied. Hence, we studied associations between diabetes and progression to metastases, PC-specific mortality (PCSM) and all-cause mortality (ACM) in men with non metastatic castrate-resistant PC (nmCRPC). Methods: Data from men diagnosed with nmCRPC between 2000 and 2017 at 8 Veterans Affairs Health Care Centers were analyzed using Cox regression to determine hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between diabetes and outcomes. Men with diabetes were classified according to (i) ICD-9/10 codes only, (ii) two HbA1c values > 6.4% (missing ICD-9/10 codes), and (iii) all diabetic men ((i) and (ii) combined). Results: Of 976 men (median age: 76 years), 304 (31%) had diabetes at nmCRPC diagnosis, of whom 51% had ICD-9/10 codes. During a median follow-up of 6.5 years, 613 men were diagnosed with metastases, and 482 PCSM and 741 ACM events occurred. In multivariable48 adjusted models, ICD-9/10 code-identified diabetes was inversely associated with PCSM (HR= 0.67; 95%CI: 0.48-0.92) while diabetes identified by high HbA1c values (no ICD-9/10 codes) was associated with an increase in ACM (HR=1.41; 95%CI: 1.16-1.72). Duration of diabetes, prior to CRPC diagnosis was inversely associated with PCSM among men identified by ICD- 9/10 codes and/or HbA1c values (HR=0.93; 95%CI: 0.88-0.98). Conclusion: In men with late-stage PC, ICD-9/10 code identified diabetes is associated with better overall survival than 'undiagnosed' diabetes identified by high HbA1c values only.
AB - Background: The prognosis of diabetic men with advanced prostate cancer (PC) is poorly understood and understudied. Hence, we studied associations between diabetes and progression to metastases, PC-specific mortality (PCSM) and all-cause mortality (ACM) in men with non metastatic castrate-resistant PC (nmCRPC). Methods: Data from men diagnosed with nmCRPC between 2000 and 2017 at 8 Veterans Affairs Health Care Centers were analyzed using Cox regression to determine hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between diabetes and outcomes. Men with diabetes were classified according to (i) ICD-9/10 codes only, (ii) two HbA1c values > 6.4% (missing ICD-9/10 codes), and (iii) all diabetic men ((i) and (ii) combined). Results: Of 976 men (median age: 76 years), 304 (31%) had diabetes at nmCRPC diagnosis, of whom 51% had ICD-9/10 codes. During a median follow-up of 6.5 years, 613 men were diagnosed with metastases, and 482 PCSM and 741 ACM events occurred. In multivariable48 adjusted models, ICD-9/10 code-identified diabetes was inversely associated with PCSM (HR= 0.67; 95%CI: 0.48-0.92) while diabetes identified by high HbA1c values (no ICD-9/10 codes) was associated with an increase in ACM (HR=1.41; 95%CI: 1.16-1.72). Duration of diabetes, prior to CRPC diagnosis was inversely associated with PCSM among men identified by ICD- 9/10 codes and/or HbA1c values (HR=0.93; 95%CI: 0.88-0.98). Conclusion: In men with late-stage PC, ICD-9/10 code identified diabetes is associated with better overall survival than 'undiagnosed' diabetes identified by high HbA1c values only.
KW - Diabetes
KW - castration-resistant prostate cancer
KW - hemoglobin A1c.
KW - metastases
KW - prostate cancer-specific mortality
UR - http://www.scopus.com/inward/record.url?scp=85169501930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85169501930&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-22-1324
DO - 10.1158/1055-9965.EPI-22-1324
M3 - Article
C2 - 37294698
AN - SCOPUS:85169501930
SN - 1055-9965
VL - 32
SP - 1208
EP - 1216
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 9
ER -